Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 16/20 | 0.89 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.75 |
| ▸ | GMNN | O75496 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.75 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.75 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22901660 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL22930771 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL22901661 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL23895049 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL22928985 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL23635844 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL24722613 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL25098577 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL20822086 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM | |
| SCHEMBL21886761 | 1.00 | STING1 (0.89) | STING1LMNARAPGEF3GMNNBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | AJ SCIENCES (YIXING) CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20210008048-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | AJ SCIENCES (YIXING) CO., LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| WO-2019170912-A1 | BIORESORBABLE CONTROLLED-RELEASE COMPOSITIONS WITH STING MODULATING MOLECULES | LIDDS AB (SE) | 2019-09-12 | — | — | WO | disclosed |
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008048-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | STING1, IL15, MAPK15 | STING1 1/4885LMNA 2650/4885RAPGEF3 1904/4885 |
| US-20190185511-A1 | LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF | STING1, TLR9, IFNAR1 | STING1 1/4885LMNA 474/4885RAPGEF3 1026/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | STING1 1/4885LMNA 2865/4885RAPGEF3 2360/4885 |
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | STING1, IRF3, CGAS | STING1 1/4885LMNA 2274/4885RAPGEF3 166/4885 |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | STING1, IRF3, CGAS | STING1 1/4885LMNA 4707/4885RAPGEF3 255/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | STING1 1/4885LMNA 4707/4885RAPGEF3 255/4885 |
| US-20240066133-A1 | THERAPEUTIC AGENTS AND CONJUGATES THEREOF | TLR9, STING1, TLR3 | STING1 2/4885LMNA 1780/4885RAPGEF3 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.